Ocrelizumab(Genentech, Inc.)은 Multiple Sclerosis 표적 항체로, Rheumatoid Arthritis 영역에서 개발·상용화 중입니다. 작용기전: target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 58건의 관련 임상이 등록되어 있습니다. PK: t½ 26 h. 차별점: novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering.
Multiple Sclerosis
Rheumatoid Arthritis
Discontinued
ADCC reporter cells for the analysis of patient sera in the con
humanized monoclonal antibody targeting CD20, approved for the treatment of adult patients with relapsing mul
novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering
target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling
Antibody-Dependent Cell-Mediated Cytotoxicity
biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Ocrelizumab(Genentech, Inc.)은 Multiple Sclerosis 표적 항체로, Rheumatoid Arthritis 영역에서 개발·상용화 중입니다. 작용기전: target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 58건의 관련 임상이 등록되어 있습니다. PK: t½ 26 h. 차별점: novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering.
Multiple Sclerosis
Rheumatoid Arthritis
Discontinued
ADCC reporter cells for the analysis of patient sera in the con
humanized monoclonal antibody targeting CD20, approved for the treatment of adult patients with relapsing mul
novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering
target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling
Antibody-Dependent Cell-Mediated Cytotoxicity
biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.